Skip to main content
Premium Trial:

Request an Annual Quote

CardioDx Closing Down

CardioDx, a medical diagnostic company that makes a blood test for heart disease, is shutting down, the San Francisco Chronicle reports.

On the same day that it boasted about its test, CardioDx informed a California state agency in mid-December that it would be closing and laying off 110 workers, the Chronicle adds.

Chronicle adds that though the firm's closing appears sudden, it comes after Medicare stopped paying for the firm's test, Corus CAD, in November. One notice posted by the US Centers for Medicare and Medicaid Services argued that the test, which gauges whether patient with chest pain might need additional testing to rule out coronary artery disease, is not medically necessary. "Data regarding its clinical usefulness in elderly (Medicare-aged) patients, particularly males, is significantly lacking in all scientific articles," it said, according to the Chronicle.

In addition, the Chronicle says the firm has been subject to whistleblower suits from former employees alleging that the company was defrauding Medicare and knew its test was unnecessary. The Chronicle notes, though, that Department of Justice said in court filings that it was not following up on the allegations.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.